89bio Inc

89bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded in January 2018 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

- Reported positive topline results from ENTRIGUE Phase 2 trial of pegozafermin in severe hypertriglyceridemia patients; initiation of Phase 3 trial expected in the first half of 2023 -

89bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

In June, 89bio Inc (NASDAQ: ETNB) announced topline results from the ENTRIGUE Phase 2 proof-of-concept study of pegozafermin for severe hypertriglyceridemia (SHTG).  SVB Leerink views these results as 'strong' and says they provide a clear win for the company as.

This Analyst Thinks 89Bio's Pegozafermin Data Has Exceeded Expectations

SAN FRANCISCO, July 05, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the closing of its upsized underwritten public offering of 18,675,466 shares of its common stock and accompanying warrants to purchase up to 9,337,733 shares of common stock at a combined public offering price of $3.55 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 7,944,252 shares of its common stock and accompanying warrants to purchase up to 3,972,126 shares of common stock at a combined public offering price of $3.549. The pre-funded warrants have an exercise price of $0.001 per share, and are exercisable immediately. The warrants have an exercise price of $5.325 per share, are exercisable immediately, and will expire two years following the date of issuance.

89bio Announces Closing of its Upsized $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

89bio Inc (NASDAQ: ETNB) announced topline results from the ENTRIGUE Phase 2 proof-of-concept study of pegozafermin for severe hypertriglyceridemia (SHTG).  Hypertriglyceridemia is characterized by high triglycerides (TG) levels, a type of fat, in the bloodstream.

89bio Posts Promising Pegozafermin Data For Severe Hypertriglyceridemia

SAN FRANCISCO, June 29, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing of its previously announced underwritten public offering of 18,675,466 shares of its common stock and accompanying warrants to purchase up to 9,337,733 shares of common stock at a combined public offering price of $3.55 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 7,944,252 shares of its common stock and accompanying warrants to purchase up to 3,972,126 shares of common stock at a combined public offering price of $3.549. The pre-funded warrants have an exercise price of $0.001 per share, and are exercisable immediately. The warrants have an exercise price of $5.325 per share, are exercisable immediately, and will expire two years following the date of issuance. The gross proceeds of the offering to 89bio, before deducting the underwriting discounts and commissions and other offering expenses payable by 89bio, are expected to be approximately $94.5 million. The offering is expected to close on or about July 1, 2022, subject to the satisfaction of customary closing conditions.

89bio, Inc. Announces Upsized Pricing of $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

SAN FRANCISCO, June 28, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, and accompanying warrants to purchase shares of its common stock. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities to be sold in the offering are being offered by 89bio.

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock, Pre-Funded Warrants and Warrants

- Trial met primary endpoint demonstrating statistically significant and clinically meaningful reductions across all doses (63% at the 27mg QW dose; p

89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

SAN FRANCISCO, June 21, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced additional pegozafermin data in non-alcoholic steatohepatitis (NASH) will be presented at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022, to be held in London, UK on June 22-26, 2022.

89bio to Present Additional Pegozafermin Data at EASL International Liver Congress™ 2022

89bio, Inc (NASDAQ: ETNB) was plunging almost 10% lower on Friday in sympathy with the general market, which saw the S&P 500 plummeting over 2%. In May, a number of analysts weighed in on 89bio following the biopharmaceutical company printing its first-quarter earnings on May 11.

89bio Pulls Back With Market — But Could The Stock Soar 250%?

- ENTRIGUE Phase 2 trial of pegozafermin in severe hypertriglyceridemia (SHTG) patients remains on track with topline data expected in the second quarter of 2022 -

89bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

– Reported positive topline results from cohort 7 in the Phase 1b/2a trial including data from new analyses demonstrating the promising therapeutic utility of pegozafermin for the treatment of NASH –

89bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

SAN FRANCISCO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors. Dr. Atkinson currently serves as Senior Vice President, Head of Commercial Manufacturing and Supply Chain of Vertex Pharmaceuticals.

89bio Announces Appointment of E. Morrey Atkinson, Ph.D.

SAN FRANCISCO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company's Management will participate in a fireside chat and one-on-one investor meetings at the SVB Leerink 11th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 12:00 PM ET.

89bio to Participate in the SVB Leerink 11ᵗʰ Annual Global Healthcare Conference

SAN FRANCISCO, Jan. 24, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced positive topline results from an open-label expansion cohort of 20 patients (Cohort 7) in the Phase 1b/2a proof-of-concept study evaluating pegozafermin (formerly BIO89-100) for the treatment of NASH.

89bio Reports Positive Topline Results from an Expansion Cohort of the Phase 1b/2a Trial of Pegozafermin (BIO89-100) for the Treatment of NASH

New sub-analysis presented at The Liver Meeting ® 2021 shows treatment with BIO89-100 reduced spleen volume by an average of 11.8% in NASH patients

89bio Presents New Data from Phase 1b/2a NASH Study Showing BIO89-100 Reduces Spleen Volume

SAN FRANCISCO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the quarter ended September 30, 2021.

89bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update

SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy LaPorte to its Board of Directors, effective immediately. Ms. LaPorte brings deep expertise and valuable experience in the industry to the Company.

89bio Announces Appointment of Kathy LaPorte to its Board of Directors

Data from a new sub-analysis of the Phase 1b/2a study in NASH shows correlation between increased liver fat and spleen volume in patients with non-cirrhotic NASH Data from a new sub-analysis of the Phase 1b/2a study in NASH shows correlation between increased liver fat and spleen volume in patients with non-cirrhotic NASH

89bio to Present New Sub-Analysis from Phase 1b/2a NASH Study of BIO89-100 at AASLD's The Liver Meeting 2021

SAN FRANCISCO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company's Management will participate in the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021.

89bio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

- Study designed to build upon positive Phase 1b/2a data and provide an early opportunity to demonstrate BIO89-100's potential benefits on histology endpoints - - Study designed to build upon positive Phase 1b/2a data and provide an early opportunity to demonstrate BIO89-100's potential benefits on histology endpoints -

89bio Completed Target Enrollment in Histology Cohort to Evaluate BIO89-100 for the Treatment of NASH

ENLIVEN Phase 2b trial in NASH expected to be initiated in 2Q21 ENLIVEN Phase 2b trial in NASH expected to be initiated in 2Q21

89bio Reports First Quarter 2021 Financial Results and Provides Corporate Update

SAN FRANCISCO, May 05, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company's Management will provide a corporate update and participate in one-on-one investor meetings at the BofA Securities 2021 Health Care Conference on Thursday, May 13, 2021 at 1:15 PM ET and the RBC Capital Markets 2021 Global Healthcare Conference on Wednesday, May 19, 2021 at 9:45 AM ET.

89bio to Present at Upcoming Investor Conferences

- Received written guidance from FDA related to trial design and agreement to use liquid formulation - - ENLIVEN trial to initiate as planned in 2Q21 -

89bio Announces Plans for Phase 2b (ENLIVEN) Trial in NASH

- Initiation of BIO89-100 Phase 2b NASH trial planned in 1H21 -

89bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

New analysis shows BIO89-100 meaningfully reduces liver fat volume and liver volume in patients with NASH New analysis shows BIO89-100 meaningfully reduces liver fat volume and liver volume in patients with NASH

News for 89bio Inc Stock (ETNB)